A University of Manchester research team has secured nearly £1 million in funding to develop snail-inspired soft robots capable of navigating the gastrointestinal tract and delivering cancer drugs directly to colorectal tumor sites. The concept draws from gastropod locomotion — slow, precise, and substrate-independent — to engineer miniature biocompatible robots that can be remotely guided through the gut via external magnetic fields, releasing their therapeutic payload only at the target site.
The clinical problem the project is solving is real and persistent: protein kinase inhibitors, a class of drugs with strong potential against colorectal cancer, are currently limited by poor tumor bioavailability and significant off-target toxicity. High systemic doses are needed to achieve efficacy, often forcing dose reductions or treatment discontinuation. Localized delivery could fundamentally change that calculus — maximizing therapeutic impact while minimizing adverse effects.